Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31421413 | 1.00 | GPR119 (0.34) | GPR119CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL18018251 | 0.81 | NR1H2 (0.41) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL31421521 | 0.81 | NR1H2 (0.41) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL21441794 | 0.81 | NR1H2 (0.41) | CHRM2CHRM1CHRM3DDB1CRBN | |
| SCHEMBL31472942 | 0.78 | LMNA (0.35) | — | |
| SCHEMBL31420833 | 0.78 | CHRM2 (0.35) | GPR119CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL31421279 | 0.78 | MEN1 (0.40) | GPR119CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL31420587 | 0.78 | MEN1 (0.40) | GPR119CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL31421605 | 0.78 | CHRM2 (0.35) | GPR119CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL26143905 | 0.77 | CHRM2 (0.45) | GPR119CHRM2CHRM1CHRM3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | GPR119 3347/4885CHRM2 4776/4885CHRM1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.